153 related articles for article (PubMed ID: 38116673)
21. Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study.
Zhou RQ; Luo J; Li LJ; Du M; Wu QC
BMC Surg; 2023 May; 23(1):114. PubMed ID: 37161374
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis.
Lin C; Cui J; Peng Z; Qian K; Wu R; Cheng Y; Yin W
Eur J Med Res; 2022 Oct; 27(1):201. PubMed ID: 36242046
[TBL] [Abstract][Full Text] [Related]
23. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
Zhang Q; Shao B; Tong Z; Ouyang Q; Wang Y; Xu G; Li S; Li H
BMC Med; 2022 Oct; 20(1):321. PubMed ID: 36184642
[TBL] [Abstract][Full Text] [Related]
24. Predictive factors of pathologically node-negative disease for HER2 positive and triple-negative breast cancer after neoadjuvant therapy.
Shi Z; Wang X; Qiu P; Liu Y; Zhao T; Sun X; Chen P; Wang C; Zhang Z; Cong B; Wang Y
Gland Surg; 2021 Jan; 10(1):166-174. PubMed ID: 33633973
[TBL] [Abstract][Full Text] [Related]
25. Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.
Chen XS; Yuan Y; Garfield DH; Wu JY; Huang O; Shen KW
PLoS One; 2014; 9(9):e108405. PubMed ID: 25247558
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
Litton JK; Beck JT; Jones JM; Andersen J; Blum JL; Mina LA; Brig R; Danso M; Yuan Y; Abbattista A; Noonan K; Niyazov A; Chakrabarti J; Czibere A; Symmans WF; Telli ML
Oncologist; 2023 Oct; 28(10):845-855. PubMed ID: 37318349
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041).
Fasching PA; Hein A; Kolberg HC; Häberle L; Uhrig S; Rübner M; Belleville E; Hack CC; Fehm TN; Janni W; Hartmann A; Erber R; Theuser AK; Brucker SY; Hartkopf AD; Untch M
Eur J Cancer; 2023 May; 184():1-9. PubMed ID: 36871424
[TBL] [Abstract][Full Text] [Related]
29. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.
Chen X; Wu X; Wu H; Gu Y; Shao Y; Shao Q; Zhu F; Li X; Qian X; Hu J; Zhao F; Mao W; Sun J; Wang J; Han G; Li C; Xia Y; Seesaha PK; Zhu D; Li H; Zhang J; Wang G; Wang X; Li X; Shu Y
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33172881
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02).
Ferreira AR; Metzger-Filho O; Sarmento RMB; Bines J
Front Oncol; 2017; 7():329. PubMed ID: 29416986
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
Li Y; Xing L; Li F; Liu H; Gan L; Yang D; Wang M; Yin X; Li H; Ren G
Front Oncol; 2021; 11():657634. PubMed ID: 34912699
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data.
Deng H; Wang L; Wang N; Zhang K; Zhao Y; Qiu P; Qi X; Zhang D; Xu F; Liu J
BMC Cancer; 2023 Jan; 23(1):29. PubMed ID: 36611131
[TBL] [Abstract][Full Text] [Related]
33. Platinum-based chemotherapy for early triple-negative breast cancer.
Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
Cochrane Database Syst Rev; 2023 Sep; 9(9):CD014805. PubMed ID: 37681577
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study.
Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X
World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial.
Chen J; Han Y; Hu Y; Feng X; Meng X; Guo S; Sun C; Chen G; Li K
BMJ Open; 2023 May; 13(5):e067767. PubMed ID: 37253491
[TBL] [Abstract][Full Text] [Related]
36. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
Nabholtz JM; Abrial C; Mouret-Reynier MA; Dauplat MM; Weber B; Gligorov J; Forest AM; Tredan O; Vanlemmens L; Petit T; Guiu S; Van Praagh I; Jouannaud C; Dubray-Longeras P; Tubiana-Mathieu N; Benmammar KE; Kullab S; Bahadoor MR; Radosevic-Robin N; Kwiatkowski F; Desrichard A; Cayre A; Uhrhammer N; Chalabi N; Chollet P; Penault-Llorca F
Ann Oncol; 2014 Aug; 25(8):1570-7. PubMed ID: 24827135
[TBL] [Abstract][Full Text] [Related]
37. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L; Jiang YZ; Wu SY; Wu J; Di GH; Liu GY; Yu KD; Fan L; Li JJ; Hou YF; Hu Z; Chen CM; Huang XY; Cao AY; Hu X; Zhao S; Ma XY; Xu Y; Sun XJ; Chai WJ; Guo X; Chen X; Xu Y; Zhu XY; Zou JJ; Yang WT; Wang ZH; Shao ZM
Clin Cancer Res; 2022 Jul; 28(13):2807-2817. PubMed ID: 35247906
[TBL] [Abstract][Full Text] [Related]
38. Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study.
Wang H; Li Y; Qi Y; Zhao E; Kong X; Yang C; Yang Q; Zhang C; Liu Y; Song Z
Front Oncol; 2022; 12():909426. PubMed ID: 35875123
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
Liang X; Chen X; Li H; Li Y
Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer.
Hou X; Shi X; Luo J
Oncol Lett; 2022 Jul; 24(1):215. PubMed ID: 35720491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]